The Court of Arbitration for Sport said today that it accepted tennis player Sara Errani had not meant to take a banned drug, but still added eight months to her ban.
The Italian, a Roland Garros finalist in 2012, was suspended for two months in August 2017 by an independent tribunal of the Italian Tennis Federation after she failed an out-of-competition test, administered at her family home, last February.
Errani said she had consumed letrozole, which can have a "marginal" anabolic effect and mask the use of testosterone, unknowingly when her mother's cancer medication somehow found its way into a family meal.
After the original ruling, both Errani, who wanted the ban overturned, and the Italian anti-doping agency, who wanted it increased, launched appeals.
On Monday, CAS issued a statement saying it accepted that the letrozole "was medication taken by her mother that found its way into the family meal prepared by the athlete's mother and eaten by the entire family".
CAS said that Errani had to be held responsible for her mother's mistake and while this amounted to a "light degree of fault", increased her ban to 10 months. The two months that Errani served last year are deducted from that total.
Errani was ranked 74th in the world before Roland Garros where she was eliminated in the first round by Alize Cornet of France on May 17.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
